FRANKLIN TEMPLETON

Franklin Genomic Advancements ETF (HELX)

Growth | Factsheet as of June 30, 2026

Investment Overview

The fund seeks capital appreciation by investing in equity securities inside and outside of the United States, including developing or emerging markets. The fund invests in companies that are relevant to its investment theme of genomic advancements that the investment manager believes are substantially focused on/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business.

Total Returns (%)

	Cumulative			Average Annual				Inception
	3-Mth	6-Mth	YTD	1-Yr	3-Yr	5-Yr	10-Yr	Inception	Date
Market Price Return	20.94	10.08	10.08	44.81	9.90	-4.93	—	7.80	2/25/2020
NAV Returns	20.94	9.98	9.98	44.86	9.88	-4.94	—	7.78	2/25/2020
Benchmark	15.44	10.88	10.88	22.82	20.35	12.31	—	15.95	—

Calendar Year Total Returns (%)

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Market Price Return	26.35	-5.32	1.13	-37.89	9.80	—	—	—	—	—
NAV Returns	25.89	-5.08	1.23	-37.86	9.66	—	—	—	—	—
Benchmark	17.15	23.81	25.96	-19.21	25.66	—	—	—	—	—

Performance data quoted represents past performance, which does not guarantee future results. *Current performance may be lower or higher than the figures shown. Principal value and investment returns will fluctuate, and investors' shares, when redeemed, may be worth more or less than the original cost. Performance would have been lower if fees had not been waived in various periods. Total returns assume the reinvestment of all distributions and the deduction of all fund expenses. An investor cannot invest directly in an index, and unmanaged index returns do not reflect any fees, expense or sales charges. Returns for periods of less than one year are not annualized. For current month-end performance, please visit franklintempleton.com.*

Net Asset Value (NAV) returns are based on the NAV of the ETF; Market Price returns are based upon the official closing price of the ETF's shares. Returns are average annualized total returns, except for those periods of less than one year, which are cumulative. Market Price returns are calculated using the closing price as of 4 p.m. Eastern time on each trading day (when NAV is normally determined for most funds), and do not represent the returns you would receive if you traded shares at other times. Performance for the ETF and its benchmark index are as of the ETF's last trading day before the end of the period.Since shares of the Fund did not trade in the secondary market until after the Fund's inception, for the period from inception to the first day of secondary trading February 27, 2020, the NAV of the Fund is used as a proxy for the Market Price to calculate market returns.

The total annual operating expenses are as of the fund's prospectus available at the time of publication. Actual expenses may be higher and may impact portfolio returns.

Growth of $10,000

Inception through June 30, 2026

Market Price Returns, assuming dividends reinvested

The Growth of $10,000 chart reflects a hypothetical $10,000 investment on Market Price and assumes reinvestment of dividends and capital gains. Fund expense, including management fees and other expenses were deducted.

Fund Overview

Fund Inception Date	02/25/2020
Total Expense Ratio (%)	0.50
ETF Category	Active
Asset Class	Equity
Listed Exchange	Cboe
Cboe Ticker	HELX
CUSIP	35473P520
ISIN	US35473P5200
Shares Outstanding	700,000

Benchmark(s)

Russell 3000 Index

Fund Characteristics

	Fund
Total Net Assets	$27.94 Million
Number of Holdings	63
Average Market Cap (Millions USD)	$65,426
Price to Book	5.92x
Price to Earnings (12-Month Trailing)	35.09x

Risk Statistics (NAV Returns) (3-Year)

	Fund	Benchmark
Standard Deviation (%)	21.65	13.20
Beta	0.99	—

Top Equity Issuers (% of Total)

	Fund
GUARDANT HEALTH INC	9.09
NATERA INC	7.46
KRYSTAL BIOTECH INC	6.33
LIGAND PHARMACEUTICALS INC	4.62
ADAPTIVE BIOTECHNOLOGIES CORP	3.99
UNITED THERAPEUTICS CORP	3.51
BRIDGEBIO PHARMA INC	3.50
ELI LILLY & CO	2.95
TWIST BIOSCIENCE CORP	2.85
VERTEX PHARMACEUTICALS INC	2.75

Sector Allocation (% of Total)

	Fund
Biotechnology	56.01
Life Sciences Tools & Services	16.83
Pharmaceuticals	12.73
Health Care Services	9.93
Fertilizers & Agricultural Chemicals	2.25
Application Software	0.97
Cash & Cash Equivalents	1.27

Market Cap Breakdown (% of Equity) (USD)

	Fund
<2.0 Billion	2.48
2.0-5.0 Billion	11.67
5.0-10.0 Billion	17.29
10.0-25.0 Billion	38.31
25.0-50.0 Billion	13.40
>50.0 Billion	16.86

Portfolio Data Information

Holdings are provided for informational purposes only and should not be construed as a recommendation to purchase or sell any security.

Portfolio Management

	Years with Firm	Years of Experience
Matthew Moberg	26	28

What should I know before investing?

All investments involve risks, including possible loss of principal. Equity securities are subject to price fluctuation and possible loss of principal. The fund's investment strategies incorporate the identification of **thematic investment opportunities,** and its performance may be negatively impacted if the investment manager does not correctly identify such opportunities or if the theme develops in an unexpected manner. By focusing its investments in health care-related industries, the fund carries much greater risks of adverse developments and price movements in such industries than a fund that invests in a wider variety of industries. **International investments** are subject to special risks, including currency fluctuations and social, economic and political uncertainties, which could increase volatility. These risks are magnified in **emerging markets.** The portfolio is **non-diversified** and may invest in a relatively small number of issuers, which may negatively impact the fund's performance and result in greater fluctuation in the value of the fund's shares. The manager may consider **environmental, social and governance (ESG) criteria** in the research or investment process; however, ESG considerations may not be a determinative factor in security selection. In addition, the manager may not assess every investment for ESG criteria, and not every ESG factor may be identified or evaluated. When the **fund's size is small,** the fund may experience low trading volume and wide bid/ask spreads. These and other risks are discussed in the fund's prospectus.

Glossary

Standard Deviation: Measure of the degree to which a fund's return varies from the average of its previous returns. The larger the standard deviation, the greater the likelihood (and risk) that a fund's performance will fluctuate from the average return. **Beta:** A measure of the fund's volatility relative to the market, as represented by the stated Index. A beta greater than 1.00 indicates volatility greater than the market. **Weighted Average Market Capitalization:** A determination of a company's value, calculated by multiplying the total number of company stock shares outstanding by the price per share. For a portfolio, the value represents a weighted average based on the stocks held. **Price to Book:** The price per share of a stock divided by its book value (i.e., net worth) per share. For a portfolio, the value represents a weighted average of the stocks it holds. **Price to Earnings (12-Month Trailing)** is the share price of a stock, divided by its per-share earnings over the past year. For a portfolio, the value represents a weighted average of the stocks it holds.

Important Information

ETFs and ETPs trade like stocks, fluctuate in market value and may trade at prices above or below the ETFs/ETPs net asset value. Brokerage commissions and ETF expenses will reduce returns.

ETF/ETP shares may be bought or sold throughout the day at their market price, not their Net Asset Value (NAV), on the exchange on which they are listed. Shares of ETFs/ETPs are tradable on secondary markets and may trade either at a premium or a discount to their NAV on the secondary market.

Canada: This content is intended only for Canadian institutional investors that qualify as "permitted clients" as defined in National Instrument 31-103 - Registration Requirements, Exemptions and Ongoing Registrant Obligations. U.S. securities laws generally limit a non-U.S. fund's purchase of a U.S. registered mutual fund or ETF/ETP (a "U.S. Fund") to no more than 3% of the U.S. Fund's voting stock. You should consult your legal counsel prior to investing in a U.S. Fund.

The **Russell 3000 Index** measures the performance of the 3,000 largest U.S. companies based on total market capitalization.

Source: FTSE. Important data provider notices and terms available at www.franklintempletondatasources.com. All data is subject to change. Franklin Distributors, LLC. Member FINRA/SIPC.

© Franklin Templeton. All rights reserved.

Before investing, carefully consider a fund's investment objectives, risks, charges and expenses. You can find this and other information in each prospectus, or summary prospectus, if available, at www.franklintempleton.com. Please read it carefully.